Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · BILL · 116th Congress · H.R. 14 (Introduced in House) — To increase the Federal commitment to defeating the virus that causes COVID–19 and prepare for future pandemics, and... · Sec. 2011

Sec. 2011. Report to Congress on barriers to domestic manufacturing of medical products and supplies

268 words·~1 min read·/bill/116/hr/14/ih/section-2011

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

Not later than January 1, 2021, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report on barriers to domestic manufacturing of active pharmaceutical ingredients, drugs, and devices that are manufactured outside of the United States. Such report shall— identify factors that limit or otherwise discourage the domestic manufacturing of active pharmaceutical ingredients, drugs, and devices that are currently manufactured outside of the United States, including any Federal, State, local, or Tribal laws and regulations that hinder domestic manufacturing opportunities; and recommend specific strategies to overcome the challenges identified under paragraph (1), including strategies— to develop effective incentives for domestic manufacturing; and to make changes to laws or regulations that hinder domestic manufacturing opportunities.
In carrying out the report under subsection (a), the Secretary shall consult with— the Food and Drug Administration, the Centers for Medicare & Medicaid Services, the Department of Defense, the Department of Commerce, the Department of State, the Department of Veterans Affairs, the Department of Justice, and any other Federal agencies as appropriate; and relevant stakeholders, including drug, device, and active pharmaceutical ingredient manufacturers, and other entities, as appropriate.
In this section, the term active pharmaceutical ingredient has the meaning given to such term in section 207.1 of title 21, Code of Federal Regulations (and any successor regulations). The Secretary shall make the report under subsection
(a)available on the public website of the Department of Health and Human Services.
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.